Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Cidara Therapeutics Inc.32 enrolled

Overview

Non-interventional extension study to investigate VVC recurrence and candida colonization following the P2 acute VVC study

Following completion of the Phase 2, multicenter, randomized, active-controlled study of the safety and tolerability of two formulations of CD101 compared to fluconazole for the treatment of moderate to severe episodes of acute vulvovaginal candidiasis (NCT07299432), subjects without a recurrence of VVC will be followed up to an additional 90 days +/- 14 days to assess candida colonization and recurrence of VVC.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Candidiasis, Vulvovaginal Yeast Infection Mycoses Moniliasis, Vulvovaginal Vaginitis, Monilial

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Enrollment in and completed the primary study through the Day 28 visit. * Received at least one dose of study drug in the primary study * Able to give written informed consent prior to completion of the primary study Exclusion Criteria: * Received systemic or topical vaginal non-study antifungal therapy at any time during the primary study * Diagnosed with bacterial vaginosis, trichomonas, gonorrhea, chlamydia, or active herpes at any point during the primary study * The Principal Investigator considers that the subject should not participate in the study

Locations (23)

Precision Trials AZ

Phoenix, Arizona, United States